CD8A and neoplasm: Ex vivo IFN-γ ELISpot assays indicated that the frequencies of the CD8+ T cells that responded to the tumor-associated peptides, which composed the vaccine, were increased after the 2nd vaccination (B2–B5, Fig. 4b).